Literature DB >> 22854709

A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis.

C J Kim1, A Nazli, O L Rojas, D Chege, Z Alidina, S Huibner, S Mujib, E Benko, C Kovacs, L Y Y Shin, A Grin, G Kandel, M Loutfy, M Ostrowski, J L Gommerman, C Kaushic, R Kaul.   

Abstract

Interleukin-22 (IL-22) is a cytokine with epithelial reparative and regenerative properties that is produced by Th22 cells and by other immune cell subsets. Therefore, we explored the hypothesis that disruption of the gut barrier during HIV infection involves dysregulation of these cells in the gastrointestinal mucosa. Sigmoid IL-22-producing T cell and Th22 cells were dramatically depleted during chronic HIV infection, epithelial integrity was compromised, and microbial translocation was increased. These alterations were reversed after long-term antiretroviral therapy. While all mucosal IL-22-producing T-cell subsets were also depleted very early during HIV infection, at these early stages IL-22 production by non-T-cell populations (including NKp44+ cells) was increased and gut epithelial integrity was maintained. Circulating Th22 cells expressed a higher level of the HIV co-receptor/binding molecules CCR5 and α4β7 than CD4+ T-cell subsets in HIV-uninfected participants, but this was not the case after HIV infection. Finally, recombinant IL-22 was protective against HIV and tumor necrosis factor-α-induced gut epithelial damage in a validated in vitro gut epithelial system. We conclude that reduced IL-22 production and Th22 depletion in the gut mucosa are important factors in HIV mucosal immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854709     DOI: 10.1038/mi.2012.72

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  93 in total

1.  Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions.

Authors:  Connie J Kim; Colin Kovacs; Tae-Wook Chun; Gabor Kandel; Brendan J W Osborne; Sanja Huibner; Kamnoosh Shahabi; Feng-Yun Yue; Erika Benko; Mario Ostowski; Rupert Kaul
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

3.  Interleukin-22 ameliorates acute severe pancreatitis-associated lung injury in mice.

Authors:  Ying-Ying Qiao; Xiao-Qin Liu; Chang-Qin Xu; Zheng Zhang; Hong-Wei Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 4.  Innate Lymphoid Cells: Their Contributions to Gastrointestinal Tissue Homeostasis and HIV/SIV Disease Pathology.

Authors:  Joseph C Mudd; Jason M Brenchley
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

5.  HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.

Authors:  S M Fernandes; A R Pires; P Matoso; C Ferreira; H Nunes-Cabaço; L Correia; E Valadas; J Poças; P Pacheco; H Veiga-Fernandes; R B Foxall; A E Sousa
Journal:  Mucosal Immunol       Date:  2017-05-17       Impact factor: 7.313

Review 6.  The gut microbiome and HIV-1 pathogenesis: a two-way street.

Authors:  Stephanie M Dillon; Daniel N Frank; Cara C Wilson
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

7.  Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.

Authors:  Danfeng Sun; Yanwei Lin; Jie Hong; Haoyan Chen; Nisha Nagarsheth; Dongjun Peng; Shuang Wei; Emina Huang; Jingyuan Fang; Ilona Kryczek; Weiping Zou
Journal:  Oncoimmunology       Date:  2015-09-02       Impact factor: 8.110

8.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

Review 9.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Will loss of your MAITs weaken your HAART [corrected]?

Authors:  Johan K Sandberg; Joana Dias; Barbara L Shacklett; Edwin Leeansyah
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.